Orlistat and antisense-miRNA-loaded PLGA-PEG nanoparticles for enhanced triple negative breast cancer therapy

Nanomedicine

Volumn 11, Issue 3, 2016, Pages 235-247

  Bhargava Shah, Aarohi ^a   Foygel, Kira ^a   Devulapally, Rammohan ^a   Paulmurugan, Ramasamy ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

anti miR; cancer therapy; orlistat; PLGA nanoparticles; TNBC

Indexed keywords

ANTINEOPLASTIC AGENT; ANTISENSE MICRORNA; CASPASE 3; COMPLEMENTARY RNA; DOXORUBICIN; MACROGOL; NANOPARTICLE; POLY(ETHYLENE GLYCOL)CONJUGATED POLY(LACTIC CO GLYCOLIC ACID)NANOPARTICLE; POLYGLACTIN; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P21; PROTEIN P53; TETRAHYDROLIPSTATIN; UNCLASSIFIED DRUG; LACTIC ACID; LACTONE; MACROGOL DERIVATIVE; MESSENGER RNA; POLYGLYCOLIC ACID; POLYLACTIC ACID-POLYGLYCOLIC ACID COPOLYMER;

ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG DIFFUSION; DRUG RELEASE; EMULSION; EVAPORATION; FIBROBLAST; HUMAN; HUMAN CELL; HYDROPHILICITY; IC50; IN VITRO STUDY; PRIORITY JOURNAL; TRIPLE NEGATIVE BREAST CANCER; FEMALE; TRIPLE NEGATIVE BREAST NEOPLASMS;

FEMALE; HUMANS; LACTIC ACID; LACTONES; POLYETHYLENE GLYCOLS; POLYGLYCOLIC ACID; RNA, ANTISENSE; RNA, MESSENGER; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 84956938853     PISSN: 17435889     EISSN: 17486963     Source Type: Journal    
DOI: 10.2217/nnm.15.193     Document Type: Article

References (26)

1. Torchilin VP. Micellar nanocarriers: Pharmaceutical perspectives. Pharm. Res. 24(1), 1-16 (2007).
2. Cho K, Wang X, Nie S, Chen ZG, Shin DM. Therapeutic nanoparticles for drug delivery in cancer. Clin. Cancer Res. 14(5), 1310-1316 (2008).
3. Haley B, Frenkel E. Nanoparticles for drug delivery in cancer treatment. Urol. Oncol. 26(1), 57-64 (2008).
4. Acharya S, Sahoo SK. PLGA nanoparticles containing various anticancer agents and tumour delivery by EPR effect. Adv. Drug Deliv. Rev. 63(3), 170-183 (2011).
5. Devulapally R, Paulmurugan R. Polymer nanoparticles for drug and small silencing RNA delivery to treat cancers of different phenotypes. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 6(1), 40-60 (2014).
6. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J. Clin. 65(2), 87-108 (2015).
7. Cascione L, Gasparini P, Lovat F et al. Integrated microRNA and mRNA signatures associated with survival in triple negative breast cancer. PLoS ONE 8(2), e55910 (2013).
8. Joensuu H, Gligorov J. Adjuvant treatments for triple-negative breast cancers. Ann. Oncol. 23(Suppl. 6), vi40-vi45 (2012).
9. Von Minckwitz G, Martin M. Neoadjuvant treatments for triple-negative breast cancer (TNBC). Ann. Oncol. 23(Suppl. 6), vi35-vi39 (2012).
10. Boyle P. Triple-negative breast cancer: epidemiological considerations and recommendations. Ann. Oncol. 23(Suppl. 6), vi7-vi12 (2012).
11. Ballinger A. Orlistat in the treatment of obesity. Expert Opin. Pharmacother. 1(4), 841-847 (2000).
12. Menendez JA, Vellon L, Lupu R. Antitumoral actions of the anti-obesity drug orlistat (Xenical™) in breast cancer cells: blockade of cell cycle progression, promotion of apoptotic cell death and PEA3-mediated transcriptional repression of Her2/neu (erbB-2) oncogene. Ann. Oncol. 16(8), 1253-1267 (2005).
13. Menendez JA, Colomer R, Lupu R. Why does tumorassociated fatty acid synthase (oncogenic antigen-519) ignore dietary fatty acids? Med. Hypotheses 64(2), 342-349 (2005).
14. Shabbits JA, Hu Y, Mayer LD. Tumor chemosensitization strategies based on apoptosis manipulations. Mol. Cancer Ther. 2(8), 805-813 (2003).
15. Devulapally R, Sekar NM, Sekar TV et al. Polymer nanoparticles-mediated codelivery of antimiR-10b and antimiR-21 for achieving triple negative breast cancer therapy. ACS Nano 9(3), 2290-2302 (2015).
16. Devulapally R, Sekar TV, Paulmurugan R. Formulation of anti-miR-21 and 4-hydroxytamoxyfen co-loaded biodegradable polymer nanoparticles and its anti-proliferative effect on breast cancer cells. Mol. Pharm. 12(6), 2080-2092 (2015).
17. Guerciolini R. Mode of action of orlistat. Int. J. Obes. Relat. Metab. Disord. 21(Suppl. 3), S12-S23 (1997).
18. Kridel SJ, Axelrod F, Rozenkrantz N, Smith JW. Orlistat is a novel inhibitor of fatty acid synthase with antitumor activity. Cancer Res. 64(6), 2070-2075 (2004).
19. Gansler TS, Hardman W, 3rd, Hunt DA, Schaffel S, Hennigar RA. Increased expression of fatty acid synthase (OA-519) in ovarian neoplasms predicts shorter survival. Hum. Pathol. 28(6), 686-692 (1997).
20. Nemoto T, Terashima S, Kogure M et al. Overexpression of fatty acid synthase in oesophageal squamous cell dysplasia and carcinoma. Pathobiology 69(6), 297-303 (2001).
21. Piyathilake CJ, Frost AR, Manne U et al. The expression of fatty acid synthase (FASE) is an early event in the development and progression of squamous cell carcinoma of the lung. Hum. Pathol. 31(9), 1068-1073 (2000).
22. Pizer ES, Lax SF, Kuhajda FP, Pasternack GR, Kurman RJ. Fatty acid synthase expression in endometrial carcinoma: correlation with cell proliferation and hormone receptors. Cancer 83(3), 528-537 (1998).
23. Rashid A, Pizer ES, Moga M et al. Elevated expression of fatty acid synthase and fatty acid synthetic activity in colorectal neoplasia. Am. J. Pathol. 150(1), 201-208 (1997).
24. Paulmurugan R, Bhethanabotla R, Mishra K et al. Folate receptor targeted polymeric micellar nanocarriers for delivery of orlistat as a repurposed drug against triple negative breast cancer. Mol. Cancer Ther. pii: molcanther. 0579. 2015 (2015) (Epub ahead of print).
25. Drew BS, Dixon AF, Dixon JB. Obesity management: update on orlistat. Vasc. Health Risk Manag. 3(6), 817-821 (2007).
26. Smith L, Watson MB, O'kane SL, Drew PJ, Lind MJ, Cawkwell L. The analysis of doxorubicin resistance in human breast cancer cells using antibody microarrays. Mol. Cancer Ther. 5(8), 2115-2120 (2006).